Another Partnership between Immunocore and MedImmune against Skin Cancer
Immunocore Limited, a world-leading biotechnology company developing novel biological drugs to treat cancer and other diseases,…
18/04/2015 - 2 minutes
Cancer: Keep up to Date with the Latest in Oncology
As one of the leading causes of death worldwide, cancer receives great focus from the life sciences industry. Indeed, it’s the largest therapeutic focus area for biotech and pharma companies, which are working on a large number of therapeutic approaches, including small molecules, T cell therapies, and antibody therapies.
Global cancer drug sales are estimated to reach €221B by 2024. The top 10 blockbuster drugs are sold by big pharma companies, like Roche, Merck, AbbVie, and Bristol-Myers Squibb. Examples of blockbusters include Keytruda, Rituxan, and Herceptin.
Biotech companies are doing a fair bit of the work as well. Read on to keep up to date with the latest oncology research, discoveries, and market developments.
Show More
Editor's Picks for Cancer
- A Cure for Cancer? How CAR-T Cell Therapy is Revolutionizing Oncology
- Immuno-Oncology: From Science Fiction to the Mainstream
- ADC Approval Buoys Spirits in Cancer Treatment Space
- Do Natural Killer Cells Hold the Key to Treating Blood Cancers?
- Meet 20 European Immuno-Oncology Companies that are Fighting Cancer
A Guide to Current Therapies in Immuno-Oncology
From a rich history to a growing number of therapies, the immuno-oncology landscape has changed rapidly over the last decade. In this report, we look into its past, discuss present therapeutic approaches, and provide an outlook into its future.
Go to ReportLatest Cancer Articles
Merck Serono bets on Oncology with the appointment of Dr. Alise Reicin
Merck Serono appointed Dr. Alise Reicin as Senior Vice President, Head of Global Clinical Development.…
17/04/2015 - 2 minutes
Cardio3, the leading Stem Cell Biotech gets a US patent on CAR-T
Just a week after announcing its intention to launch an IPO in the United States,…
08/04/2015 - 2 minutes
Apceth Initiates Phase II for its pioneering Engineered Cell Therapy to treat Gastrointestinal Cancer
After successfully complete phase I clinical study, apceth initiates the Phase II of world’s first…
26/03/2015 - 2 minutes
Epigenomics’ proColon, the non-invasive blood-based test for colorectal cancer
Epigenomics, the German-American cancer molecular diagnostics company, completed the enrollment for its ADMIT trial (AD herence…
25/03/2015 - 3 minutes
Rigontec and its revolutionary RNA-based immunotherapeutics raise €4.8 Million
Rigontec has raised €4.8M in the second closing of its Series A financing round from Forbion…
24/03/2015 - 3 minutes
New Oncology finances its Genetic Test for Cancer Diagnosis
New Oncology completed a financing round to prepare the market launch of NEOliquid, a non-invasive…
17/03/2015 - 2 minutes
First Treatment Approved under Early Access to Medicine Scheme (EAMS)
Today, it has been accepted! The first drug approved through the Early Access to Medicine Scheme…
11/03/2015 - 2 minutes
The Promising Company OSE Pharma launches an IPO
Created in 2012 by Emile Loria and Dominique Costantini, OSE Pharma is a European cancer…
10/03/2015 - 3 minutes
MorphoSys and Emergent BioSolutions Initiate Phase I
MorphoSys AG and Emergent BioSolutions will initiate a Phase I clinical study to evaluate the…
09/03/2015 - 3 minutes
Novartis announces completion of transactions with GSK
Completes transactions with GSK including: acquisition of GSK oncology portfolio, creation of Consumer Healthcare joint…
05/03/2015 - 5 minutes
Bristol-Myers Squibb signs an agreement for Bavarian Nordic’s PROSTVAC
Bristol-Myers Squibb signs an exclusive agreement with Bavarian Nordic for PROSTVAC, a prostate-specific antigen-targeting cancer…
04/03/2015 - 2 minutes
